| Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics CG Santos-Gallego, JA Requena-Ibanez, R San Antonio, K Ishikawa, ... Journal of the American College of Cardiology 73 (15), 1931-1944, 2019 | 533 | 2019 |
| Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction CG Santos-Gallego, AP Vargas-Delgado, JA Requena-Ibanez, ... Journal of the American College of Cardiology 77 (3), 243-255, 2021 | 369 | 2021 |
| Pathophysiology of acute coronary syndrome CG Santos-Gallego, B Picatoste, JJ Badimón Current atherosclerosis reports 16, 1-9, 2014 | 315 | 2014 |
| Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study JA Requena-Ibáñez, CG Santos-Gallego, A Rodriguez-Cordero, ... Heart Failure 9 (8), 578-589, 2021 | 170 | 2021 |
| Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia … CG Santos-Gallego, TP Vahl, G Goliasch, B Picatoste, T Arias, K Ishikawa, ... Circulation 133 (10), 954-966, 2016 | 167 | 2016 |
| Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration: Magnetic Resonance … B Ibanez, G Vilahur, G Cimmino, WS Speidl, A Pinero, BG Choi, MU Zafar, ... Journal of the American College of Cardiology 51 (11), 1104-1109, 2008 | 154 | 2008 |
| Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study CG Santos-Gallego, JA Requena-Ibanez, R San Antonio, ... Cardiovascular Imaging 14 (2), 393-407, 2021 | 150 | 2021 |
| Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type B Ibanez, C Giannarelli, G Cimmino, CG Santos-Gallego, M Alique, ... Atherosclerosis 220 (1), 72-77, 2012 | 115 | 2012 |
| The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments A Garcia-Ropero, JJ Badimon, CG Santos-Gallego Expert opinion on drug metabolism & toxicology 14 (12), 1287-1302, 2018 | 114 | 2018 |
| SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure L Tilemann, A Lee, K Ishikawa, J Aguero, K Rapti, C Santos-Gallego, ... Science translational medicine 5 (211), 211ra159-211ra159, 2013 | 112 | 2013 |
| Beginning to understand high-density lipoproteins CG Santos-Gallego, JJ Badimon, RS Rosenson Endocrinology and Metabolism Clinics 43 (4), 913-947, 2014 | 110 | 2014 |
| Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model J Aguero, K Ishikawa, L Hadri, C Santos-Gallego, K Fish, N Hammoudi, ... American Journal of Physiology-Heart and Circulatory Physiology 307 (8 …, 2014 | 98 | 2014 |
| Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-γ, transforming growth factor-β1, and a Smad2-dependent mechanism S Redondo, E Ruiz, CG Santos-Gallego, E Padilla, T Tejerina Diabetes 54 (3), 811-817, 2005 | 98 | 2005 |
| Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure K Ishikawa, KM Fish, L Tilemann, K Rapti, J Aguero, CG Santos-Gallego, ... Molecular therapy 22 (12), 2038-2045, 2014 | 86 | 2014 |
| Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-β S Redondo, CG Santos-Gallego, P Ganado, M García, L Rico, M Del Rio, ... Circulation 107 (4), 626-629, 2003 | 83 | 2003 |
| HDL-cholesterol: Is it really good?: Differences between apoA-I and HDL CG Santos-Gallego, B Ibanez, JJ Badimon Biochemical pharmacology 76 (4), 443-452, 2008 | 75 | 2008 |
| Role of HDL in those with diabetes CG Santos-Gallego, RS Rosenson Current cardiology reports 16, 1-14, 2014 | 70 | 2014 |
| Metabolism of the failing heart and the impact of SGLT2 inhibitors A Garcia-Ropero, CG Santos-Gallego, MU Zafar, JJ Badimon Expert opinion on drug metabolism & toxicology 15 (4), 275-285, 2019 | 68 | 2019 |
| Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model J Aguero, K Ishikawa, L Hadri, CG Santos-Gallego, KM Fish, ... Journal of the American College of Cardiology 67 (17), 2032-2046, 2016 | 67 | 2016 |
| Rationale and design of the EMPA-TROPISM trial (ATRU-4): are the “cardiac benefits” of empagliflozin independent of its hypoglycemic activity? CG Santos-Gallego, A Garcia-Ropero, D Mancini, SP Pinney, ... Cardiovascular drugs and therapy 33, 87-95, 2019 | 66 | 2019 |
Valentin FusterCentro Nacional de Investigaciones Cardiovasculares (CNIC)在 cnic.es 的电子邮件经过验证
